Fu M, Naci H, Booth CM, et al. - Over the past decade, a substantial increase in the use of new cancer drugs without documented clinical benefit has been reported, accounting for substantial spending.

• This cross-sectional study involved 37,348 patients who received 1 or more of 44 new oral targeted cancer drugs between 2011 and 2018.

• The proportion of patients taking drugs without documented overall survival advantage rose from 13% in 2011 to 59% in 2018, accounting for 52% of the $3.5 billion estimated cumulative expenditure on the new oral targeted cancer drugs by the end of 2018.